Key result
In patients with cardiogenic shock, 30-day mortality with Impella support was 47.8%, with improved survival associated with Impella 5.0 or CP use and initiation prior to revascularization.
Why the study?
The clinical impact of invasive hemodynamic support with Impella in patients with cardiogenic shock remained to be defined.
Does Impella improve short term mortality in patients with cardiogenic shock?
Meta-Analysis (n=3,933)
Does Impella improve short term mortality in patients with cardiogenic shock?
In patients with cardiogenic shock, 30-day mortality remains high at 47.8% despite Impella use, though Impella CP/5.0 and early initiation prior to PCI or cardiac arrest may be associated with improved survival.
Answers are grounded in this paper and cite their sources.
Mortality exceeds 45% with Impella in CS; leaves open whether device type or pre-PCI timing improves outcomes in prospective trials.
INTRODUCTION: The clinical impact of invasive hemodynamic support with Impella in patients with cardiogenic shock (CS) remains to be defined. METHOD: Only studies including patients treated with Impella in CS were selected. The primary endpoint was short term mortality, while secondary endpoints were major vascular complications and major bleeding. RESULTS: 17 studies and 3933 patients were included in the analysis. Median age was 61.9 (IQR 59.2-63.5) years, CS was mainly related to acute coronary syndrome (ACS): 79.6% (IQR 75.1-79.6). Thirty-day mortality was 47.8% (CI 43.7-52%). Based on metaregression analysis, the Impella 5.0 (point estimate -0.006, 95% CI -0.01 - - 0.02, p < 0.01) and the Impella CP (point estimate -0.007, 95% CI -0.01 - - 0.03, p < 0.01) devices were related to a higher survival rate, whereas the Impella 2.5 was not. Furthermore, a correlation with reduced mortality was found when Impella was initiated in CS not complicated by cardiac arrest (CA), and before revascularization, (point estimate 0.01, 95% CI 0.002-0.02, p < 0.01 and point estimate -0.02, 95% CI 0.023-0.01, p < 0.001 respectively). The vascular complication and major bleeding rate were 7.4% (95% CI 5.6-9.6%) and 15.2% (95% CI 10.7-21%) respectively, and were associated with older age and comorbidities, while the implantation of an Impella CP/2.5 L was associated with fewer complications. CONCLUSIONS: Despite the use of Impella the 30 day mortality of CS still remains high. Our data suggest that the use of an Impella CP, initiation of Impella prior to PCI and in patients without cardiac arrest was correlated with outcome improvements.
No takes yet. Share an insight, caveat, or question.
Iannaccone et al. (2020) conducted a meta-analysis in Cardiogenic shock (n=3,933). Impella was evaluated on Short term mortality. In patients with cardiogenic shock, 30-day mortality with Impella support was 47.8%, with improved survival associated with Impella 5.0 or CP use and initiation prior to revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: